Need for multicriteria evaluation of generic drug policies

Z. Kaló, Anke Peggy Holtorf, Rafael Alfonso-Cristancho, Jie Shen, Tamás Ágh, András Inotai, Diana Brixner

Research output: Article

17 Citations (Scopus)

Abstract

Policymakers tend to focus on improving patented drug policies because they are under pressure from patients, physicians, and manufacturers to increase access to novel therapies. The success of pharmaceutical innovation over the last few decades has led to the availability of many off-patent drugs to treat disease areas with the greatest public health need. Therefore, the success of public health programs in improving the health status of the total population is highly dependent on the efficiency of generic drug policies. The objective of this article was to explore factors influencing the true efficiency of generic prescription drug policies in supporting public health initiatives in the developed world. Health care decision makers often assess the efficiency of generic drug policies by the level of price erosion and market share of generics. Drug quality, bioequivalence, in some cases drug formulations, supply reliability, medical adherence and persistence, health outcomes, and nondrug costs, however, are also attributes of success for generic drug policies. Further methodological research is needed to measure and improve the efficiency of generic drug policies. This also requires extension of the evidence base of the impact of generic drugs, partly based on real-world evidence. Multicriteria decision analysis may assist policymakers and researchers to evaluate the true value of generic drugs.

Original languageEnglish
Pages (from-to)346-351
Number of pages6
JournalValue in Health
Volume18
Issue number2
DOIs
Publication statusPublished - márc. 1 2015

Fingerprint

Generic Drugs
Public Health
Pharmaceutical Preparations
Therapeutic Equivalency
Drug Compounding
Prescription Drugs
Decision Support Techniques
Health Status
Research Personnel
Delivery of Health Care
Physicians
Pressure
Costs and Cost Analysis
Health
Research

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health
  • Medicine(all)

Cite this

Kaló, Z., Holtorf, A. P., Alfonso-Cristancho, R., Shen, J., Ágh, T., Inotai, A., & Brixner, D. (2015). Need for multicriteria evaluation of generic drug policies. Value in Health, 18(2), 346-351. https://doi.org/10.1016/j.jval.2014.12.012

Need for multicriteria evaluation of generic drug policies. / Kaló, Z.; Holtorf, Anke Peggy; Alfonso-Cristancho, Rafael; Shen, Jie; Ágh, Tamás; Inotai, András; Brixner, Diana.

In: Value in Health, Vol. 18, No. 2, 01.03.2015, p. 346-351.

Research output: Article

Kaló, Z, Holtorf, AP, Alfonso-Cristancho, R, Shen, J, Ágh, T, Inotai, A & Brixner, D 2015, 'Need for multicriteria evaluation of generic drug policies', Value in Health, vol. 18, no. 2, pp. 346-351. https://doi.org/10.1016/j.jval.2014.12.012
Kaló Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A et al. Need for multicriteria evaluation of generic drug policies. Value in Health. 2015 márc. 1;18(2):346-351. https://doi.org/10.1016/j.jval.2014.12.012
Kaló, Z. ; Holtorf, Anke Peggy ; Alfonso-Cristancho, Rafael ; Shen, Jie ; Ágh, Tamás ; Inotai, András ; Brixner, Diana. / Need for multicriteria evaluation of generic drug policies. In: Value in Health. 2015 ; Vol. 18, No. 2. pp. 346-351.
@article{7a43065b2b55437cacc495611d43cfb0,
title = "Need for multicriteria evaluation of generic drug policies",
abstract = "Policymakers tend to focus on improving patented drug policies because they are under pressure from patients, physicians, and manufacturers to increase access to novel therapies. The success of pharmaceutical innovation over the last few decades has led to the availability of many off-patent drugs to treat disease areas with the greatest public health need. Therefore, the success of public health programs in improving the health status of the total population is highly dependent on the efficiency of generic drug policies. The objective of this article was to explore factors influencing the true efficiency of generic prescription drug policies in supporting public health initiatives in the developed world. Health care decision makers often assess the efficiency of generic drug policies by the level of price erosion and market share of generics. Drug quality, bioequivalence, in some cases drug formulations, supply reliability, medical adherence and persistence, health outcomes, and nondrug costs, however, are also attributes of success for generic drug policies. Further methodological research is needed to measure and improve the efficiency of generic drug policies. This also requires extension of the evidence base of the impact of generic drugs, partly based on real-world evidence. Multicriteria decision analysis may assist policymakers and researchers to evaluate the true value of generic drugs.",
keywords = "adherence, drug policies, generic drug, multicriteria decision analysis, price erosion, real-world evidence",
author = "Z. Kal{\'o} and Holtorf, {Anke Peggy} and Rafael Alfonso-Cristancho and Jie Shen and Tam{\'a}s {\'A}gh and Andr{\'a}s Inotai and Diana Brixner",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.jval.2014.12.012",
language = "English",
volume = "18",
pages = "346--351",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Need for multicriteria evaluation of generic drug policies

AU - Kaló, Z.

AU - Holtorf, Anke Peggy

AU - Alfonso-Cristancho, Rafael

AU - Shen, Jie

AU - Ágh, Tamás

AU - Inotai, András

AU - Brixner, Diana

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Policymakers tend to focus on improving patented drug policies because they are under pressure from patients, physicians, and manufacturers to increase access to novel therapies. The success of pharmaceutical innovation over the last few decades has led to the availability of many off-patent drugs to treat disease areas with the greatest public health need. Therefore, the success of public health programs in improving the health status of the total population is highly dependent on the efficiency of generic drug policies. The objective of this article was to explore factors influencing the true efficiency of generic prescription drug policies in supporting public health initiatives in the developed world. Health care decision makers often assess the efficiency of generic drug policies by the level of price erosion and market share of generics. Drug quality, bioequivalence, in some cases drug formulations, supply reliability, medical adherence and persistence, health outcomes, and nondrug costs, however, are also attributes of success for generic drug policies. Further methodological research is needed to measure and improve the efficiency of generic drug policies. This also requires extension of the evidence base of the impact of generic drugs, partly based on real-world evidence. Multicriteria decision analysis may assist policymakers and researchers to evaluate the true value of generic drugs.

AB - Policymakers tend to focus on improving patented drug policies because they are under pressure from patients, physicians, and manufacturers to increase access to novel therapies. The success of pharmaceutical innovation over the last few decades has led to the availability of many off-patent drugs to treat disease areas with the greatest public health need. Therefore, the success of public health programs in improving the health status of the total population is highly dependent on the efficiency of generic drug policies. The objective of this article was to explore factors influencing the true efficiency of generic prescription drug policies in supporting public health initiatives in the developed world. Health care decision makers often assess the efficiency of generic drug policies by the level of price erosion and market share of generics. Drug quality, bioequivalence, in some cases drug formulations, supply reliability, medical adherence and persistence, health outcomes, and nondrug costs, however, are also attributes of success for generic drug policies. Further methodological research is needed to measure and improve the efficiency of generic drug policies. This also requires extension of the evidence base of the impact of generic drugs, partly based on real-world evidence. Multicriteria decision analysis may assist policymakers and researchers to evaluate the true value of generic drugs.

KW - adherence

KW - drug policies

KW - generic drug

KW - multicriteria decision analysis

KW - price erosion

KW - real-world evidence

UR - http://www.scopus.com/inward/record.url?scp=84925009662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925009662&partnerID=8YFLogxK

U2 - 10.1016/j.jval.2014.12.012

DO - 10.1016/j.jval.2014.12.012

M3 - Article

C2 - 25773570

AN - SCOPUS:84925009662

VL - 18

SP - 346

EP - 351

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 2

ER -